Related Experiment Video
Updated: Sep 13, 2025
09:31
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
7.3K
Innovative Molecules and Delivery Technologies Enabling the Future of GLP-1-based Therapies
Yining Xu1, Daniel J Drucker2, Giovanni Traverso3,4,5
1Department of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Endocrine Reviews
|August 4, 2025
Summary
New GLP-1 therapies aim to overcome limitations of current treatments for metabolic diseases. Research focuses on oral small-molecule agonists and advanced drug delivery systems to improve patient outcomes.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Gut hormones are key therapeutic targets for metabolic diseases.
- Current treatments like GLP-1 receptor agonists face challenges such as cost and administration methods.
Purpose of the Study:
- To review challenges in clinical application and development of GLP-1-based pharmacotherapies.
- To explore novel therapeutic strategies and drug delivery systems for improved metabolic disease treatment.
Main Methods:
- Review of current literature on GLP-1-based therapies.
- Analysis of emerging drug delivery technologies including oral small molecules, injectables, and devices.
- Discussion of research challenges and opportunities.
Main Results:
- Limitations of current GLP-1 therapies include cost, injections, and frequent administration.
- Novel approaches include oral small-molecule agonists and advanced delivery systems like implants and smart devices.
- Research is progressing on nutrient-induced cell therapies and noninvasive delivery.
Conclusions:
- Overcoming clinical challenges requires innovation in GLP-1 drug development and delivery.
- Patient-oriented needs and endocrinological effects should guide future therapeutic advancements.
- Improved therapies have the potential to enhance patient compliance and clinical outcomes in metabolic diseases.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
419
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
419
01:06Oral Hypoglycemic Agents: Glinides
263
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263
01:23Dipeptidyl Peptidase 4 Inhibitors
260
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
260
01:27Insulin Formulations: Types and Delivery
272
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
272
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
262
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
262
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
298
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
298